What is the long-term trend for Pediatrix Medical Group's cash and cash equivalents, end of period?

Over 5 years (2020 to 2025), Pediatrix Medical Group's cash and cash equivalents, end of period has grown at a -19.7% compound annual growth rate (CAGR), from $1.12B to $375.24M.

Pediatrix Medical Group MD Cash and cash equivalents, end of period

Cash and cash equivalents, end of period at other companies

Arthur J. GallagherAJG

$8.48B-61.9%

3MMMM

$3.73B-41.1%

Phillips 66PSX

$5.15B+246%

eBayEBAY

$4.23B+1.9%

American Financial GroupAFG

$1.35B+6.0%

Erie Indemnity CompanyERIE

$268.62M+3.2%

Other financials

Income statement

See full

Revenue$476.2M+3.9%

Operating income$41.7M+29.8%

Net income$29.6M+42.6%

EPS (diluted)$0.36+50.0%

Balance sheet

See full

Cash & equivalents$205.8M+108%

Total debt$629.7M-3.9%

Total equity$878.6M+11.3%

Total assets$2.1B+3.9%

Cash flow

See full

Operating cash flow-$129.8M-10.5%

CapEx$6.2M+88.3%

Free cash flow-$136.1M-12.7%

Valuation

See full

Market cap$1.99B+42.9%

Enterprise value$2.41B+22.3%

P/E11.4×—

P/S1×+0.3×

Profitability

See full

Operating margin11.3%—

Net margin9%—

FCF margin12.3%+2.5pp

Returns & leverage

See full

Return on equity20.9%—

Debt / equity0.7×-0.1×

Current ratio1.3×-0.5×

Where this comes from

Reported directly by Pediatrix Medical Group in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: Pediatrix Medical Group’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pediatrix Medical Group's cash and cash equivalents, end of period.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pediatrix Medical Group's cash and cash equivalents, end of period?: Pediatrix Medical Group (MD) reported cash and cash equivalents, end of period of $205.78M in Q1 2026.
How has Pediatrix Medical Group's cash and cash equivalents, end of period changed year-over-year?: Pediatrix Medical Group's cash and cash equivalents, end of period increased by 107.9% year-over-year, from $98.98M to $205.78M.
What is the long-term trend for Pediatrix Medical Group's cash and cash equivalents, end of period?: Over 5 years (2020 to 2025), Pediatrix Medical Group's cash and cash equivalents, end of period has grown at a -19.7% compound annual growth rate (CAGR), from $1.12B to $375.24M.